Biocatalysis Comes of Age: Redefining Small Molecule API Synthesis

For much of modern pharmaceutical history, synthetic organic chemistry has been the engine of small molecule drug manufacturing. The first industrial enzymes, such as lipases and oxidoreductases, were introduced decades ago but found only limited use, primarily in chiral resolution and simple hydrolysis reactions. Early efforts were hindered by narrow substrate specificity, poor stability under process conditions, and limited understanding of how to adapt enzymes to non-natural reactions. As a result, biocatalysis remained a niche curiosity rather than a mainstream element of route design.

That has changed dramatically in recent years. Across the industry, sustainability and process-efficiency mandates have converged to create powerful incentives for greener, more selective chemistry. Traditional multi-step syntheses, reliant on metal catalysts, protecting-group chemistry, and high-energy solvents, are being reevaluated as companies face tighter environmental, social, and governance (ESG) goals and pressure to reduce waste and energy use.^1,2 At the same time, the economics of development favor shorter, more convergent routes that can move candidates from lab to launch with fewer unit operations and smaller environmental footprints.

These overlapping pressures have positioned biocatalysis at the center of a manufacturing transformation. Once viewed as too niche or fragile for commercial production, enzymatic processes are now integral to the synthesis of high-value active pharmaceutical ingredients (APIs), particularly those requiring stereo- and regioselective transformations. The technology has moved far beyond early lipase-based resolutions to encompass entire enzyme families — transaminases, ketoreductases, monooxygenases, and nitrilases — capable of constructing complex molecules with precision that purely chemical catalysis struggles to match.^3,4

Biocatalysis in the context of small molecule APIs context is distinct from biomanufacturing of biologics or peptides; it applies the tools of enzymology to chemical synthesis rather than to recombinant expression of macromolecular products. The chemistry-to-biology shift in catalysis represents not just a cleaner route but a fundamentally different way of designing, optimizing, and scaling pharmaceutical synthesis.

The momentum behind biocatalysis is no longer driven solely by scientific curiosity or the pursuit of green chemistry credentials. Instead, it reflects a confluence of industrial, regulatory, and economic forces that now make enzymatic catalysis a practical necessity. Biocatalytic routes routinely outperform conventional chemistry on key process metrics, from yield and selectivity to solvent and energy consumption, while offering more predictable scale-up and compliance advantages.

One of the clearest advantages of biocatalysis lies in its ability to dramatically reduce environmental impact. Enzymatic reactions typically operate under mild conditions — ambient temperature and pressure, aqueous or low-toxicity solvents, and near-neutral pH — eliminating the need for hazardous reagents and extreme conditions that generate waste and by-products. As a result, biocatalytic processes achieve significantly lower E-factors, meaning less waste per kilogram of API produced.^5,6 These reductions translate directly into lower downstream treatment costs and reduced environmental liabilities, aligning with corporate sustainability targets and regulatory expectations for cleaner manufacturing.

Compared with metal-catalyzed systems, enzymatic routes also minimize the need for heavy-metal catalysts and the associated purification burdens. Many reactions that would otherwise require multiple protection and deprotection steps can be performed directly on functionalized intermediates, reducing both solvent volumes and cycle times. This efficiency extends to energy usage: reactions that once required high heat or cryogenic control can often be run at room temperature without compromising selectivity.^7,8 As global energy costs rise and carbon accounting becomes embedded in manufacturing audits, these inherent efficiencies provide both an economic and environmental dividend.

The regulatory and ESG implications are equally significant. Regulators increasingly encourage greener chemistry through programs that reward sustainable innovation and life cycle impact reduction. For global CDMOs and API manufacturers, enzymatic processes facilitate compliance with evolving frameworks for solvent recovery, effluent treatment, and carbon footprint reduction. The use of biocatalysts also fits neatly within formal green chemistry metrics, such as process mass intensity (PMI) and carbon efficiency.⁹ In many organizations, these metrics are now integrated into key performance indicators for process development teams, further institutionalizing the shift toward enzymatic synthesis.

Beyond sustainability, biocatalysis has become a powerful lever for process intensification. Enzymes’ exquisite selectivity often allows chemists to telescope multiple steps into a single operation, particularly in functional group interconversions and chiral transformations. This telescoping capability shortens reaction sequences, reduces intermediate isolation steps, and cuts both solvent use and processing time.¹⁰ In an industry where every stage of purification represents cost, time, and yield loss, the ability to combine steps without compromising product quality is transformative.

Late-stage functionalization offers another advantage. Enzymes can selectively modify complex intermediates without perturbing other sensitive moieties, enabling faster optimization of analog series and late differentiation of drug candidates. The same precision applies to the installation of stereocenters, traditionally one of the most resource-intensive challenges in small-molecule synthesis. Engineered transaminases, ketoreductases, and monooxygenases can produce enantiopure intermediates in a single step, avoiding the need for expensive chiral auxiliaries or metal catalysts.^4,11 The outcome is a leaner, more convergent process that can move from pilot to production with fewer scale-up surprises.

What began as a sustainability play has become a route-efficiency imperative. In today’s process development environment, biocatalysis is no longer the greener alternative — it is often the best available synthesis path: shorter, cleaner, and cheaper by design.

The industrial rise of biocatalysis has been underpinned by rapid advances in enzyme discovery, engineering, and integration with traditional synthetic chemistry. Once constrained by the limited natural diversity of enzymes, chemists and biotechnologists now command a broad and expanding toolkit capable of addressing virtually every type of bond construction or transformation in small molecule synthesis. The underlying shift is both technological and conceptual: enzymes are no longer biological curiosities but modular, programmable catalysts that can be rationally tuned for synthetic objectives.

A relatively small number of enzyme families account for most industrial biocatalysis today. Transaminases, ketoreductases, and monooxygenases have become workhorses for chiral amine and alcohol formation, while hydrolases remain invaluable for ester and amide bond transformations. Nitrilases and amidases, once specialized tools, are now routinely applied to construct or resolve key intermediates with high regio- and stereoselectivity. These enzymes collectively enable cleaner synthetic routes for a wide range of pharmaceutical scaffolds, particularly those incorporating nitrogen- and oxygen-containing functional groups.

The discovery pipeline for new biocatalysts has expanded dramatically. Metagenomic mining — searching environmental DNA for novel sequences — has uncovered vast libraries of enzymes with desirable catalytic activities.^12,13 Many of these naturally occurring enzymes exhibit promiscuous or previously unknown reactivity, offering starting points for subsequent optimization. Coupled with high-throughput screening platforms, metagenomics allows chemists to access unprecedented functional diversity, effectively converting the natural biosphere into a searchable catalogue of potential catalysts.

The next leap forward has come from the deliberate reengineering of enzymes to perform reactions foreign to nature. Computational design now enables predictive modeling of enzyme active sites, guiding the introduction of mutations that expand substrate range or alter catalytic mechanism.^11,14 Machine learning and data-driven modeling accelerate this process further by correlating sequence variations with performance outcomes, reducing the need for purely empirical screening.^15,16 These tools shorten the design–build–test cycle and allow iterative refinement of catalysts in weeks rather than months.

One of the most remarkable achievements of this approach is the creation of enzymes that catalyze so-called “abiological” reactions: transformations that nature never evolved to perform. Engineered cytochromes and heme proteins can now insert carbene and nitrene intermediates into C–H bonds, carry out asymmetric cyclopropanation, and mediate reactions once thought exclusive to organometallic catalysis.^4,8 This convergence between enzymatic and chemical reactivity is erasing old boundaries and establishing a new discipline of synthetic enzymology where the logic of directed evolution complements the precision of molecular modeling.

Modern process design rarely treats biocatalysis as an isolated operation. Instead, it is increasingly embedded within hybrid chemoenzymatic sequences that pair enzymatic selectivity with the versatility of traditional organic synthesis. Enzymatic steps can introduce or resolve stereocenters early in a route, setting the stage for downstream chemical elaboration, or they can perform late-stage functionalizations inaccessible to conventional catalysis. In either case, the result is a seamless interplay between biological and chemical transformations that maximizes overall yield and efficiency.

Flow-based systems and continuous reactors have further expanded the industrial utility of biocatalysis. Immobilized enzymes can be packed into flow modules, allowing precise control of residence time, temperature, and substrate concentration while enabling catalyst reuse.^10,17 Advances in carrier materials and cross-linking chemistry have greatly improved enzyme stability under process conditions, allowing sustained operation at production scale. Additional strategies, such as enzyme encapsulation, cofactor recycling, and solvent engineering, are extending catalyst lifetimes and broadening the range of compatible reaction media.¹⁸

The result is a manufacturing paradigm in which the distinction between chemistry and biology is increasingly blurred. Engineered enzymes now perform reactions that once defied biological possibility, transforming the way small molecules are conceived, synthesized, and scaled for the pharmaceutical marketplace.

The industrial maturation of biocatalysis can best be understood through the lens of its application: how specific enzymes have been deployed to replace or augment traditional chemical steps in API manufacturing. From pioneering examples that validated the approach to recent breakthroughs that expand its reach into previously inaccessible chemistry, these cases illustrate how enzyme-enabled synthesis has evolved from proof of concept to mainstream practice.

The enzymatic synthesis of sitagliptin remains the definitive case study in modern biocatalysis. Developed by Merck & Co. and Codexis, the replacement of a rhodium-catalyzed asymmetric hydrogenation with an engineered transaminase established a new benchmark for green and efficient route design. The biocatalytic step reduced waste, eliminated heavy-metal residues, and improved overall yield and enantiopurity, all while simplifying the downstream process. This milestone demonstrated that an enzymatic approach could not only meet but exceed the performance of state-of-the-art chemical catalysis in a large-scale, regulatory-compliant context.

Building on that success, collaborations among Novartis, DSM, and Codexis have further expanded the reach of biocatalysis. These partnerships have focused on multi-enzyme cascades that combine two or more sequential enzymatic transformations in a single vessel. By designing reaction conditions compatible with multiple catalysts, these systems enable the one-pot synthesis of chiral amines, alcohols, and complex heterocycles from simple precursors.³ Such cascades reduce intermediate handling and purification, yielding substantial efficiency gains that translate directly to commercial advantage.

More recent advances have pushed biocatalysis into the realm of late-stage and non-natural transformations. Engineered oxygenases now perform direct C–H amination and halogenation with high selectivity, enabling modification of advanced intermediates without pre-functionalization.^4,14 These transformations, which once required multiple protection and redox steps, can now be achieved in a single biocatalytic operation, dramatically simplifying route design for drug-like scaffolds.

Similarly, new classes of aminotransferases and reductive aminases have been tailored for asymmetric amination and reductive alkylation, enabling the installation of chiral centers at sterically hindered or electronically complex positions.^7,11 These enzymes are not only valuable for early-route construction but are increasingly applied in process intensification for late intermediates, providing the flexibility to tailor APIs or analogs rapidly within a development program.

Continuous biocatalytic flow systems represent another frontier. By immobilizing enzymes in packed-bed reactors, manufacturers can achieve consistent, long-duration operation under steady-state conditions. Flow systems offer tight control over residence time, temperature, and substrate concentration while allowing real-time monitoring of conversion and product quality.^10,17 They also lend themselves to modular integration with downstream chemical or purification steps, creating the foundation for end-to-end continuous manufacturing of small-molecule APIs.

Despite these advances, industrial implementation has required pragmatic solutions to longstanding challenges in enzyme cost, stability, and supply. The economics of enzyme use have improved dramatically through more efficient expression systems, immobilization technologies, and the emergence of specialized enzyme suppliers, but issues of long-term stability and cofactor management still demand attention.⁹

Integrating enzymatic steps into multiproduct GMP environments has introduced new operational considerations. Cleaning validation and cross-contamination controls must be adapted to the biological nature of catalysts, particularly when immobilized systems are reused across campaigns. Nevertheless, experience across several CDMOs and innovators suggests that these challenges are now largely procedural rather than technological.

Regulatory acceptance has followed accordingly. Both ICH Q7 and Q11 frameworks comfortably accommodate biocatalytic steps as part of GMP-compliant API manufacture, provided enzyme sources, inactivation procedures, and impurity profiles are well-documented.^5,6 As a result, enzyme-catalyzed transformations are increasingly viewed as routine, not exceptional—a sign that biocatalysis has fully entered the industrial mainstream of pharmaceutical process chemistry.

The rapid ascent of biocatalysis has coincided with an equally transformative wave of digital innovation. The combination of artificial intelligence (AI), machine learning (ML), and high-performance computing is rewriting the way enzymes are discovered, optimized, and deployed in process development. What was once an empirical and time-consuming pursuit requiring screening thousands of enzyme variants for a single desired transformation has evolved into a computationally guided discipline capable of predicting catalytic performance before a single experiment is run.

Advances in protein-structure prediction have made it possible to explore enzyme sequence space with unprecedented precision. Tools, such as AlphaFold and RoseTTAFold, can now accurately predict the three-dimensional structures of enzymes from amino acid sequences, enabling in silico screening of active-site geometries and binding modes.¹⁵ These models not only accelerate enzyme identification but also facilitate the rational design of mutations to enhance selectivity, activity, and stability.

Complementing these predictive capabilities are quantum mechanical and molecular dynamics models that simulate enzyme–substrate interactions at the atomic level.^14,16 By modeling transition states and reaction pathways, researchers can pinpoint rate-limiting steps, understand cofactor behavior, and visualize subtle conformational changes that govern reactivity. Together, these computational tools have turned enzyme engineering into a data-rich, iterative process that combines structural insight with predictive analytics to shorten development cycles and improve catalytic outcomes.

The concept of the digital twin — an executable virtual model of a real-world process — is now being applied to biocatalytic manufacturing. Digital twins integrate enzyme kinetics, substrate solubility, mass-transfer characteristics, and flow dynamics into a unified simulation that mirrors plant-scale behavior. By coupling these models with real-time process analytical technology (PAT) and ML feedback loops, developers can predict and optimize process parameters long before scale-up.^10,11 This capability is particularly valuable for continuous biocatalytic systems, where reaction efficiency depends on precise control of residence time, substrate concentration, and temperature gradients.

Digital twins also enable the dynamic adjustment of process conditions based on live sensor data, supporting adaptive control strategies that maintain product quality despite feedstock variability or enzyme deactivation. This convergence of simulation, automation, and analytics represents the next step in quality by design (QbD): not just documenting process understanding but embedding it directly into control architectures.

The digital transformation of biocatalysis extends beyond individual laboratories to a broader ecosystem of shared data and collective learning. Publicly accessible enzyme databases, such as BRENDA, SABIO-RK, and UniProt, have become foundational resources, providing kinetic constants, substrate ranges, and structural annotations that fuel AI model training. These repositories are increasingly complemented by open-access enzyme libraries from academic and industrial collaborations.

Equally important are collaborative engineering initiatives like the NICE consortium, which pool data, algorithms, and protein design expertise to accelerate enzyme development across the sector.⁹ Such open innovation frameworks are helping to standardize enzyme characterization protocols and promote interoperability between data sets, essential foundations for large-scale AI model refinement.

In aggregate, these advances have turned enzyme discovery from an empirical art into a computational science. The integration of structural prediction, simulation, and data sharing is flattening the learning curve for biocatalysis, ensuring that new enzymes and the processes that they enable reach industrial maturity faster than ever before.

Realizing the full industrial potential of biocatalysis requires translating laboratory breakthroughs into robust, compliant, and economically viable manufacturing processes. This transition from bench to plant is not merely a matter of scaling reaction volumes; it entails the reconfiguration of equipment, workflows, and mindsets within the pharmaceutical manufacturing ecosystem. Today, advances in process intensification, facility design, and regulatory adaptation are converging to make biocatalysis a standard element of API production rather than an experimental exception.

The key to successful scale-up lies in process intensification — the integration of biocatalytic steps into compact, continuous, and self-sustaining systems. Immobilization technologies have been central to this progress. By fixing enzymes onto solid supports or encapsulating them in polymeric matrices, manufacturers can achieve higher catalyst stability, simplified separation, and multiple cycles of reuse. Coupled with cofactor recycling systems, these approaches significantly reduce reagent costs and waste streams, improving the overall process mass intensity of API synthesis.^10,17

Continuous flow biocatalysis represents the next stage of this evolution. Flow reactors allow precise control over temperature, residence time, and substrate concentrations, maintaining enzyme activity while enabling real-time adjustments. Integrated workups where reaction, separation, and purification occur in a single sequence further reduce downtime and solvent consumption. These intensified designs are increasingly supported by PAT, which provides real-time measurements of enzyme kinetics, conversion rates, and impurity profiles to ensure consistent quality and regulatory compliance.⁴

Contract development and manufacturing organizations (CDMOs) have played a decisive role in scaling biocatalysis, building multipurpose platforms that accommodate both enzymatic and chemical processes. Many are investing in modular suites equipped with adaptable reactor systems, immobilized enzyme modules, and flexible downstream purification equipment.³ This adaptability allows CDMOs to integrate biocatalytic steps within traditional small molecule campaigns, expanding their service portfolios without the need for dedicated biological manufacturing infrastructure.

Mixed-mode suites where enzymatic and chemical transformations coexist present unique challenges. Facility design must account for differences in solvent compatibility, temperature control, and cleaning validation, particularly when biological materials are reused. These hybrid environments demand rigorous risk assessment and cross-functional coordination between process chemists, analytical scientists, and engineers. At the organizational level, success also depends on cultural change: process development teams must learn to think biologically, incorporating enzyme behavior, kinetics, and expression logistics into route design decisions that were once purely chemical.

Training has therefore become a critical investment area. Forward-looking CDMOs are building internal “biocatalysis academies” and embedding interdisciplinary teams that pair synthetic chemists with enzymologists and data scientists. This blending of expertise is accelerating technology transfer and reducing the friction traditionally associated with introducing new catalytic paradigms into established GMP settings.

The industrialization of biocatalysis also extends upstream into enzyme sourcing and supply chain strategy. Some pharmaceutical companies now produce key enzymes in-house using recombinant expression systems, allowing tighter control over sequence, quality, and intellectual property. Others rely on specialized suppliers that provide custom-engineered enzymes, immobilization supports, and recycling systems on a just-in-time basis. The latter model offers flexibility but introduces logistical dependencies that must be carefully managed, especially for multi-product campaigns or high-volume production.

Regulatory expectations have evolved in parallel. Authorities now expect full traceability of enzyme origin, production host, and purification methods, as well as comprehensive impurity profiling to rule out residual proteins, nucleic acids, or endotoxins.^5,6 Guidance under ICH Q7 and Q11 reinforces the need for documented risk assessment and control strategies for all biocatalytic steps. Far from hindering adoption, these standards have provided a clear framework for compliance, allowing manufacturers to deploy enzymatic processes with the same confidence as any conventional chemical route.

Taken together, these developments signal that biocatalysis has fully entered the industrial mainstream. The tools and infrastructure required to scale enzymatic chemistry are now in place, supported by a maturing regulatory environment and a manufacturing culture increasingly attuned to biology’s logic.

Biocatalysis is no longer just a scientific tool; it has become a strategic differentiator. For both CDMOs and originator pharmaceutical companies, the adoption of enzymatic synthesis is reshaping competitive positioning, sustainability narratives, and long-term cost structures. What was once an optional enhancement to route design has evolved into a core capability that defines operational efficiency, environmental impact, and client appeal.

From a business perspective, the advantages are measurable. Biocatalytic routes often deliver substantial reductions in raw material usage, waste generation, and energy consumption, translating directly into lower cost-per-kilogram metrics and higher yield per reactor hour. These process economics, once secondary to yield and purity, are now central to procurement and portfolio decisions as ESG frameworks become embedded in corporate reporting. Manufacturing partners that can demonstrate tangible carbon and waste reductions increasingly stand apart in the CDMO marketplace, where clients seek not only technical excellence but also alignment with their sustainability commitments.

This new calculus extends beyond compliance or public perception. For CDMOs, the ability to offer fully developed biocatalytic platforms complete with enzyme discovery, optimization, and integration into continuous manufacturing provides a powerful means of differentiation. It signals a level of technical sophistication and innovation readiness that aligns with the most advanced pharmaceutical pipelines. As enzymatic processes become more standardized, early adoption today positions these organizations to lead in efficiency-driven, low-footprint manufacturing tomorrow.

The next phase in this evolution is likely to be characterized by an “enzyme-first” mindset in route design. Historically, enzymes were introduced late in development to retrofit existing synthetic routes with greener alternatives. That paradigm is shifting: process chemists are now beginning to design syntheses around biocatalytic steps from the outset, using enzyme availability and selectivity as foundational criteria rather than constraints. This inversion represents a major cultural shift in pharmaceutical development that aligns chemistry with biology not as a replacement but as a guiding principle.

The lessons learned from small molecule biocatalysis are also influencing other modalities. The same logic of selective, sustainable catalysis is being extended into hybrid API–peptide–oligonucleotide platforms, where enzyme-enabled transformations can simplify conjugation, modify backbones, or generate stereochemically pure intermediates.^18,19 In these cross-modality systems, the convergence of chemical and biological synthesis is opening new routes to molecular architectures that were once beyond reach.

In this way, biocatalysis is emerging as more than a technological breakthrough; it is a redefinition of pharmaceutical manufacturing strategy. It aligns operational efficiency with environmental responsibility and connects molecular innovation directly to competitive advantage.

The trajectory of biocatalysis over the past decade suggests that its current momentum is only the beginning. What was once a niche discipline is rapidly becoming a central pillar of process innovation, and its evolution over the next five to 10 years will likely redefine how small molecules, and perhaps most pharmaceutical products, are conceived, synthesized, and manufactured.

In the near term, the expansion of biocatalysis into non-natural substrate space will be a major frontier. Engineered enzymes are increasingly capable of accommodating substrates that bear fluorinated, heteroaromatic, or sterically hindered scaffolds, unlocking new avenues for medicinal chemistry and late-stage diversification. The ability to introduce specific modifications into complex molecules without extensive re-optimization could transform how structure–activity relationships are explored in discovery and how candidate molecules are optimized for production.

Equally transformative will be the emergence of AI-native enzyme–process design loops. These systems will integrate machine learning, digital twins, and high-throughput experimentation into unified workflows where enzyme design, route simulation, and process optimization occur simultaneously. Instead of separate stages of discovery, development, and scale-up, biocatalytic processes will evolve dynamically through iterative computational and experimental feedback. Such integration will enable real-time adaptation to new substrates or process conditions, marking the transition from static to intelligent manufacturing systems.

Continuous manufacturing will be the natural partner to these digital capabilities. As more enzymes are immobilized or stabilized for long-term use, continuous biocatalytic reactors will become standard features in multiproduct facilities. This shift will bring not only efficiency and quality advantages but also new flexibility in scaling, allowing manufacturers to adjust output dynamically in response to market demand without costly batch requalification. Integration of cofactor recycling, inline purification, and closed-loop control will further reduce resource intensity and enable truly end-to-end continuous API production.

Regulatory harmonization will accompany these technological advances. Recent updates, such as ICH Q14 and Q2(R2), emphasize model-based process understanding and analytical robustness, both of which align naturally with data-driven enzymatic workflows. As regulatory agencies gain familiarity with enzyme use, source characterization, and life cycle management, biocatalysis will move from a point of review scrutiny to a point of regulatory confidence, streamlining approvals and facilitating global technology transfer.

Looking ahead, a “fully enzymatic” manufacturing ecosystem would integrate all these dimensions: enzymes designed through AI-guided evolution, processes optimized through real-time simulation, and production carried out in continuous, digitally controlled facilities powered by renewable inputs. Such a system would be inherently adaptive, sustainable, and efficient, mirroring the logic of biological evolution itself.

The most profound change biocatalysis brings is not simply greener chemistry but the re-architecture of pharmaceutical manufacturing around evolution’s own principles of selectivity, adaptability, and continuous improvement, marking a redefinition of not only catalysis and routing but of biopharmaceutical innovation.

References

1. Becker, Tonia. “The Evolution of API Route Decisions.” Pharma Manufacturing.  22 Apr. 2019.

2. Challener, Cynthia. “The Enzymatic Catalysis Route to Going Green.” Pharmaceutical Technology. 7 Sep. 2016.

3. Buzzanca, Jacopo. “The (R)evolution of Biocatalysis in API Synthesis.” Manufacturing Chemist. 3 May 2024.

4. Bell, Elizabeth L, et al. “Strategies for designing biocatalysts with new functions.” Chemical Society Reviews. 53: 1320–1350 (2024).

5. Hollmann, Frank, and Roberto Fernandez-Lafuente. “Grand Challenges in Biocatalysis.” Frontiers in Catalysis. 1: 633893 (2021).

6. Rabion, Alain, et al. “Accelerating the implementation of biocatalysis in pharmaceutical research and development portfolio.” Comptes Rendus Chimie. 28: 507–520 (2025).

7. Paul, Caroline, et al. “Enzyme engineering for biocatalysis.” Molecular Catalysis. 555: 113874 (2024).

8. Edrem, Elif, and John M Woodley. “Industrially useful enzymology: Translating biocatalysis from laboratory to process.” Cell Reports Physical Science (Chem Catalysis). 2: P2499–2505 (2022.

9. Wohlgemuth, Roland, Jennifer Littlechild, and Byung-Gee Kim. “Editorial: Systems biocatalysis for bioprocess design.” Frontiers in Bioengineering and Biotechnology. 8 Nov. 2022.

10. Rocha, Raquel A, Robert E Speight, and Colin Scott. “Engineering Enzyme Properties for Improved Biocatalytic Processes in Batch and Continuous Flow.” Organic Process Research & Development. 15 Feb. 2022.

11. France, Scott P, Russell D Lewis, and Carlos A Martinez. “The Evolving Nature of Biocatalysis in Pharmaceutical Research and Development.” JACS. 27 Feb. 2023.

12. Simic, Stefan, et al. “Shortening Synthetic Routes to Small Molecule Active Pharmaceutical Ingredients Employing Biocatalytic Methods.” Chemical Reviews. 122: 1052–1126 (2021.

13. Fernandez-Lucas, Jesus. “Biocatalysis: An Eco-Friendly Scenario for the Manufacturing of APIs.” International Journal of Molecular Sciences. 24: 4474 (2023).

14. Paton, Alexandra E, et al. “Connecting chemical and protein sequence space to predict biocatalytic reactions.” Nature. 626: 108–116 (2025).

15. Leveson-Gower, Reuben B. “Designing Enzymatic Reactivity with an Expanded Palette.” Chembiochem. 25: e2025000076 (2025).

16. Ding, Yaoyu, et al. “Redesigning Enzymes for Biocatalysis: Exploiting Structural Understanding for Improved Selectivity.” Front. Mol. Biosci. 9: 908275 (2022).

17. De Gonzalo, Gonzalo, et al. “Biocatalysis for the asymmetric synthesis of Active Pharmaceutical Ingredients (APIs): this time is for real.” Expert Opinion on Drug Metabolism & Toxicology. 10: 1159–1171 (2022).

18. Kinner, Alina, et al. “Recent Advances in Biocatalysis for Drug Synthesis.” Biomedicines. 10: 964 (2022).

19. Lathan, Johathan, et al. “Directed Evolution of Enzymes Driving Innovation in API Manufacturing at GSK.” In Applied Biocatalysis: The Chemist's Enzyme Toolbox, edited by R. Patel. Wiley (2020): Chapter 1.